CHRS [NASD]
Coherus BioSciences, Inc.
Index- P/E- EPS (ttm)-3.60 Insider Own1.92% Shs Outstand77.75M Perf Week-0.71%
Market Cap691.11M Forward P/E- EPS next Y-1.46 Insider Trans0.00% Shs Float71.61M Perf Month-12.11%
Income-278.60M PEG- EPS next Q-0.83 Inst Own- Short Float / Ratio14.20% / 8.04 Perf Quarter8.37%
Sales239.10M P/S2.89 EPS this Y-334.40% Inst Trans-1.47% Short Interest10.17M Perf Half Y-26.21%
Book/sh-1.25 P/B- EPS next Y54.90% ROA-47.00% Target Price17.75 Perf Year-31.66%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range5.58 - 14.11 Perf YTD6.31%
Dividend- P/FCF- EPS past 5Y-4.60% ROI-52.00% 52W High-40.33% Beta0.88
Dividend %- Quick Ratio2.50 Sales past 5Y11.40% Gross Margin71.60% 52W Low50.88% ATR0.60
Employees376 Current Ratio2.60 Sales Q/Q-45.00% Oper. Margin- RSI (14)47.89 Volatility4.85% 6.92%
OptionableYes Debt/Eq- EPS Q/Q-128.60% Profit Margin- Rel Volume0.46 Prev Close8.40
ShortableYes LT Debt/Eq- EarningsNov 08 AMC Payout- Avg Volume1.26M Price8.42
Recom2.40 SMA20-7.15% SMA505.38% SMA200-3.05% Volume588,065 Change0.24%
Jun-14-22Initiated UBS Neutral $7
Mar-07-22Downgrade JP Morgan Overweight → Neutral $15
Jul-16-20Initiated BofA Securities Neutral $20
Apr-17-20Initiated SunTrust Buy $26
Aug-13-19Initiated Mizuho Buy
Aug-02-19Reiterated Maxim Group Buy $25 → $27
Aug-02-19Reiterated H.C. Wainwright Buy $28 → $29
Jun-11-19Initiated Barclays Overweight $30
May-07-19Initiated H.C. Wainwright Buy $28
Aug-28-18Initiated H.C. Wainwright Buy $28
Show Previous Ratings
Feb-03-23 05:30PM
Jan-30-23 05:57PM
Jan-09-23 08:20AM
Jan-04-23 07:01AM
Jan-03-23 07:12AM
08:16AM Loading…
Dec-25-22 08:16AM
Dec-24-22 12:01AM
Dec-21-22 06:52AM
Nov-10-22 06:18AM
Nov-08-22 05:25PM
04:01PM
Nov-01-22 07:30AM
Oct-18-22 10:48AM
Oct-12-22 07:30AM
Oct-10-22 11:49AM
07:30AM Loading…
Sep-19-22 07:30AM
Sep-12-22 08:30AM
Sep-02-22 09:55AM
Aug-29-22 08:49PM
Aug-19-22 09:55AM
Aug-06-22 05:00AM
Aug-04-22 05:25PM
04:01PM
Aug-03-22 09:55AM
Aug-02-22 07:15PM
Aug-01-22 11:15PM
Jul-28-22 04:01PM
Jul-18-22 10:59AM
Jul-06-22 08:00AM
Jun-27-22 08:34AM
04:30PM Loading…
Jun-22-22 04:30PM
May-11-22 06:00PM
09:47AM
May-10-22 08:45AM
May-07-22 01:30AM
May-05-22 05:35PM
04:01PM
08:31AM
May-03-22 09:45PM
May-02-22 04:09PM
09:22AM
07:40AM
07:00AM
Apr-29-22 04:01PM
08:45AM
Apr-28-22 03:02PM
Apr-20-22 02:25PM
Apr-14-22 08:30AM
Apr-08-22 01:10PM
Apr-05-22 04:30PM
06:59AM
Mar-29-22 09:15AM
Mar-22-22 04:30PM
Mar-15-22 08:00AM
07:30AM
Mar-04-22 04:05PM
08:00AM
Feb-18-22 12:00AM
Feb-17-22 05:15PM
04:01PM
Feb-15-22 04:30PM
Feb-14-22 08:30AM
Feb-11-22 08:30AM
Feb-07-22 05:25PM
09:38AM
08:30AM
Jan-10-22 07:30AM
Jan-07-22 08:30AM
Jan-04-22 08:32AM
Dec-20-21 07:59AM
05:36AM
Dec-17-21 09:09AM
Dec-16-21 04:30PM
Dec-15-21 09:08PM
Dec-13-21 07:00AM
07:00AM
Nov-18-21 06:45PM
Nov-16-21 09:08AM
Nov-15-21 08:30AM
08:30AM
Nov-11-21 05:46AM
Nov-10-21 04:15PM
Nov-08-21 10:00PM
05:25PM
04:01PM
Nov-05-21 08:30AM
Nov-01-21 07:30AM
07:30AM
Oct-29-21 04:12PM
Oct-28-21 03:05PM
Oct-11-21 08:30AM
Oct-05-21 12:52PM
08:00AM
Oct-04-21 08:00AM
Oct-01-21 01:09PM
Sep-30-21 11:11AM
Sep-29-21 04:30PM
Sep-28-21 10:11AM
Sep-24-21 04:15PM
Sep-17-21 07:39AM
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.